MedPath

Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

Recruiting
Conditions
Hypertension
Primary Aldosteronism
Registration Number
NCT06569589
Lead Sponsor
Jens Titze
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Inclusion Criteria:<br><br> 1. Age 21-70 years, with arterial hypertension or suspected to have primary<br> aldosteronism based on Endocrine Society Guidelines.<br><br> 2. Male and female patients older than 21 years.<br><br> 3. Willingness to participate and ability to provide informed consent.<br><br>Exclusion Criteria:<br><br> 1. Patients with exclusion criteria for the MRI, such as:<br><br> - implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear<br> implants)<br><br> - iron-based tattoos<br><br> - any other pieces of metal or devices that are not MR-Safe anywhere in the body<br><br> - patients who exhibit noticeable anxiety and/or claustrophobia into the MRI<br> scanner<br><br> - pregnancy<br><br> 2. Diagnosis of heart failure NYHA classes III and IV<br><br> 3. Impaired renal function with eGFR<30 ml/min or proteinuria > 1 g/24h<br><br> 4. Liver disease with cirrhosis (Child-Pugh class C) or hypoalbuminemia<br><br> 5. Muscular dystrophies<br><br> 6. Patients with active cancer or severe comorbid conditions likely to compromise<br> survival or study participation<br><br> 7. Unwillingness or other inability to cooperate

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patients with primary aldosteronism have a 10-20% higher muscle Na+ content compared to healthy controls
Secondary Outcome Measures
NameTimeMethod
High K+ intake reduces muscle Na+ in patients with primary aldosteronism;MR blockade reduces muscle Na+ conten in patients with primary aldosteronism;Compared to MR blockade, adenoma surgical removal is more efficient in reducing muscle Na+ in patients with primary aldosteronism
© Copyright 2025. All Rights Reserved by MedPath